Table 2.
Predictors of progression-free survival.
| Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| Cut off | HR | 95% CI | P | HR | 95% CI | P | ||
| Age (y) | 66 | 0.96 | 0.37–2.43 | 0.9281 | ||||
| cT stage | 2 | 4.86 | 1.84–14.16 | 0.0014 | 4.22 | 1.64–18.73 | 0.0280 | * |
| GS | 7 | 3.06 | 1.00–13.25 | 0.0488 | 1.78 | 0.24–36.35 | 0.6028 | |
| TST (ng/dL) | 4.64 | 0.69 | 0.26–1.76 | 0.4364 | ||||
| PSA (ng/mL) | 7.90 | 1.74 | 0.70–4.51 | 0.2284 | ||||
| 4F2hc Score | High/Low | 4.59 | 1.65–16.25 | 0.0027 | 11.54 | 1.16–276.67 | 0.0357 | * |
| LAT1 Score | High/Low | 2.68 | 0.87–11.64 | 0.0886 | ||||
| SKP2 Score | High/Low | 6.92 | 1.83–45.07 | 0.0029 | 0.73 | 0.14–6.99 | 0.7534 | |
HR = Cox proportional hazard ratio, 95% CI = 95% confidence interval, cT stage = clinical tumour stage, GS = Gleason score, TST = testosterone, PSA = prostate-specific antigen.
*Statistical significance (p < 0.05).